Design Therapeutics Inc (NASDAQ:DSGN) shares, rose in value on Thursday, April 16, with the stock price up by 3.55% to the previous day’s close as strong demand from buyers drove the stock to $3.50.
Actively observing the price movement in the last trading, the stock closed the session at $3.38, falling within a range of $3.36 and $3.59. The value of beta (5-year monthly) was 1.824. Referring to stock’s 52-week performance, its high was $7.77, and the low was $2.60. On the whole, DSGN has fluctuated by -27.54% over the past month.
With the market capitalization of Design Therapeutics Inc currently standing at about $198.67 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-09.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that DSGN’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of DSGN currently trading nearly -4.21% and -17.62% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 44.00, while the 7-day volatility ratio is showing 11.52% which for the 30-day chart, stands at 11.34%. Furthermore, Design Therapeutics Inc (DSGN)’s beta value is 1.81, and its average true range (ATR) is 0.39.
A comparison of Design Therapeutics Inc (DSGN) with its peers suggests the former has fared considerably weaker in the market. DSGN showed an intraday change of 3.55% in last session, and over the past year, it shrunk by -5.15%%.
Data on historical trading for Design Therapeutics Inc (NASDAQ:DSGN) indicates that the trading volumes over the past 10 days have averaged 0.19 and over the past 3 months, they’ve averaged 153.27K. According to company’s latest data on outstanding shares, there are 56.75 million shares outstanding.
Nearly 45.62% of Design Therapeutics Inc’s shares belong to company insiders and institutional investors own 43.08% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 3.32 million shares as on 2025-03-31, resulting in a short ratio of 21.97. According to the data, the short interest in Design Therapeutics Inc (DSGN) stood at 1292.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 3.22 million. The stock has fallen by -43.27% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the DSGN stock heading into the next quarter.
